BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12806951)

  • 1. [Malignancy-associated hypercalcemia].
    Oura S
    Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of malignancy-associated hypercalcemia].
    Endo I; Inoue D
    Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcemic complication in patients with oral squamous cell carcinoma.
    Iwase M; Takemi T; Manabe M; Nagumo M
    Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercalcemia and bone resorption in malignancy.
    Walls J; Bundred N; Howell A
    Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic possibilities in paraneoplastic hypercalcemia].
    Schürer CC; Peters U; Fischer JT
    Med Welt; 1981 Aug; 32(32-33):1219-21. PubMed ID: 6456397
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR; Minoofar PN
    Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bisphosphonates for resistant hypercalcemia in children with acute lymphoblastic leukemia: report of two cases and review of the literature.
    Andiran N; Alikaşifoğlu A; Küpeli S; Yetgin S
    Turk J Pediatr; 2006; 48(3):248-52. PubMed ID: 17172070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
    Coleman RE
    Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy of hypercalcemia due to malignancy.
    Raue F; Pecherstorfer M
    Recent Results Cancer Res; 1994; 137():138-60. PubMed ID: 7878293
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercalcemia of malignancy remains a clinically relevant problem.
    Van Poznak C
    Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.